Delfi Diagnostics
Baltimore, US · Founded 2018 · Delaware corporation · 10 known investors
DELFI Diagnostics develops FirstLook Lung, a blood-based laboratory test for lung cancer screening that identifies genome-wide alterations in individuals eligible for screening. The test offers an alternative to low-dose CT imaging for patients meeting USPSTF criteria and is made available to health systems, primary care providers, and lung screening programs.
Founders & leadership
Delfi Diagnostics was founded in 2018 by Victor Velculescu.
VV
Victor VelculescuFounder
PB
Peter BachExecutive
JB
Jennifer BuechelExecutive
DS
Douglas SchenkelExecutive
ND
Nicholas DracopoliExecutive
Board
RG
MD
EH
Elizabeth HomansBoard director
JK
Justin KaoBoard director
JV
Jacob Van NaardenBoard director
Investors · 10
AV8 VenturesPalo Alto · $500K – $10M
Foresite CapitalWest Hollywood
Illumina VenturesFoster City
Menlo VenturesSan Francisco · $1M – $20Mvia Greg Yap · board
Open Field CapitalNew York
OrbiMedNew York · $1M – $75M
OUP (Osage University Partners)Bala Cynwyd · $1M – $20M
Samsara BioCapitalPalo Alto
Windham Capital PartnersNew York · $1M – $5M
NVIDIAreportedSanta Clara
Reported raises · per SEC filings
Form D private placements$365.9M disclosed across 5 rounds · 2018–2025
▶$34.3MraisedDec 2025 · 50 investors · BiotechnologyRule 506(b)
▶$34.3MraisedDec 2025 · 50 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peter B. BachExecutive Officer
- Lee-Ann Smith-FreemanExecutive Officer
- Victor VelculescuDirector
- Susan TousiExecutive Officer, Director
- Amoolya SinghExecutive Officer
- Elizabeth HomansDirector
- Rishi GuptaDirector
- Jacob Van NaardenDirector
- Michael DybbsDirector
- Greg YapDirector
- Justin KaoDirector
- Offering amount
- $60M
- Amount sold
- $34.3M
- First sale
- Dec 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$225MraisedJul 2022 · 44 investors · BiotechnologyRule 506(b)
▶$225MraisedJul 2022 · 44 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peter BachExecutive Officer
- Elizabeth HomansDirector
- Rishi GuptaDirector
- Justin KaoDirector
- Jennifer BuechelExecutive Officer
- Victor VelculescuExecutive Officer, Director, Promoter
- Greg YapDirector
- Douglas SchenkelExecutive Officer
- Michael DybbsDirector
- Jacob Van NaardenDirector
- Nicholas DracopoliExecutive Officer
- Offering amount
- $225M
- Amount sold
- $225M
- First sale
- Jun 2022
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$101.1MraisedJan 2021 · 25 investors · BiotechnologyRule 506(b)
▶$101.1MraisedJan 2021 · 25 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Victor VelculescuExecutive Officer, Director
- Greg YapDirector
- Nicholas DracopoliExecutive Officer
- William StevensExecutive Officer
- Offering amount
- $101.1M
- Amount sold
- $101.1M
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$5.5MraisedAug 2019 · 7 investors · BiotechnologyRule 506(b)
▶$5.5MraisedAug 2019 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nicholas DracopoliExecutive Officer
- Victor VelculescuExecutive Officer, Director
- Greg YapDirector
- William StevensExecutive Officer
- Offering amount
- $5.5M
- Amount sold
- $5.5M
- First sale
- Aug 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$15.3KraisedAug 2019 · 9 investors · BiotechnologyRule 506(b)
▶$15.3KraisedAug 2019 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nicholas DracopoliExecutive Officer
- William J. StevensExecutive Officer
- Victor VelculescuExecutive Officer, Director
- Offering amount
- $15.3K
- Amount sold
- $15.3K
- First sale
- Jun 2018
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Delphi8 shared keywordsDelphi is an AI-powered assistant platform that helps venture capitalists scale their investment operations by automating deal screening, founder communication, and thought leadership distribution. The platform trains on a VC's own content and investment thesis to provide personalized feedback to founders and manage deal flow 24/7.
IDbyDNA7 shared keywordsScalable, high throughput DNA sequencing platforms.
Companies competing with Delfi Diagnostics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Venture funding drops in Seattle area as AI boom reshapes startup world – GeekWiregeekwire.com · Jul 2026Frequently asked questions
- What does Delfi Diagnostics do?
- DELFI Diagnostics develops FirstLook Lung, a blood-based laboratory test for lung cancer screening that identifies genome-wide alterations in individuals eligible for screening. The test offers an alternative to low-dose CT imaging for patients meeting USPSTF criteria and is made available to health systems, primary care providers, and lung screening programs.
- Who founded Delfi Diagnostics?
- Delfi Diagnostics was founded by Victor Velculescu in 2018.
- Who are Delfi Diagnostics's investors?
- Delfi Diagnostics's investors include AV8 Ventures, Foresite Capital, Illumina Ventures, Menlo Ventures, Open Field Capital, OrbiMed, OUP (Osage University Partners), Samsara BioCapital and 2 more.
- How much funding has Delfi Diagnostics raised?
- Delfi Diagnostics has disclosed $365.9M raised across 5 rounds.
- Where is Delfi Diagnostics headquartered?
- Delfi Diagnostics is headquartered in Baltimore, US.